TEVA - Sanofi Teva Pledge $1.5B To Target Inflammatory Bowel Disease That Impacts Almost 10M People | Benzinga
Sanofi SA (NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) have collaborated to co-develop and co-commercialize asset TEV ‘574.
TEV ‘574 is currently in Phase 2b clinical trials for ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease.
Under the terms of the new collaboration agreement, Teva will receive an upfront payment of €469 million ($500 million) and up to €940 million ($1 billion) in development and launch milestones.
Each company will equally share the development costs globally and net profits and losses in major markets, with other markets subject to a royalty arrangement.
Sanofi will lead the ...